Merck scraps another late-stage Alzheimer's drug study |
|
NEW YORK (Reuters) - Merck & Co Inc on Tuesday said it will end another late-stage trial of an Alzheimer's drug because it was unlikely to work, adding to the pile-up of failures to find an effective treatment for the mind-wasting disease.
|
|
|
Novartis gains U.S. approval for delayed MS drug |
|
ZURICH (Reuters) - Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market.
|
|
|
Amerisource deal may not keep Walgreens competitive: analysts |
|
(Reuters) - Walgreens' potential deal for drug distributor AmerisourceBergen will boost its cash flow and push it deeper into a lucrative specialty pharmacy market, but may fail to keep it competitive in an evolving U.S. healthcare sector, analysts said.
|
|
|
|
|
|
|
|
Related Video |
|
|
|
|
|
|
|
|
|
|
A quick-fix on the day's news delivered when you want it. Register Today |
|
|
|
|
|
A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today |
|
|
|
» » MORE NEWSLETTERS |
|
|